Oncode Accelerator

Oncode Accelerator

Research Services

Outsmarting cancer. Impacting lives.

About us

Oncode Accelerator aims to optimize and accelerate the development of new cancer therapies to address the unmet medical need.

Industry
Research Services
Company size
2-10 employees
Type
Nonprofit
Founded
2023
Specialties
Oncology, Research, Cancer therapies, and preclinical therapeutic development

Employees at Oncode Accelerator

Updates

  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    🔬 CAR T-cell therapy further explored 🔬 For a long time, the perception has been that CAR T-cell therapy has little potential in the treatment of solid tumors. However, a recent publication showed that CAR T-cell therapy could have effect in solid tumors. The effect is still limited but there is already follow-up research that gives reason to think that future prospects are better. Workstream lead Cell and Gene therapy, John Haanen, is leader of the immunotherapy research theme and program director of the Center for Cell Therapy at our partner, the Antoni van Leeuwenhoek. He describes the developments in the world of CAR T-cells in the article below. 👇

    Toepassing CAR T-celtherapie verkend voor solide tumoren | MedNet

    Toepassing CAR T-celtherapie verkend voor solide tumoren | MedNet

    https://www.mednet.nl

  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    🌟 Interesting to read! 🌟 Read the first blog by the Oncode Accelerator team on the network of the Federation of European Biochemical Societies (FEBS). The blog will give you more insight about the Innovation Platforms and Workstreams within the program and our first call for Demonstrator Projects. Read the blog via the link below 👇 #FEBS #CancerResearch #Innovation

    View organization page for FEBS, graphic

    3,973 followers

    Do you work in the development of preclinical cancer therapies? The Oncode Accelerator program has an open call for Demonstrator Projects. They offer access to state-of-the-art equipment, expertise, facilities and technologies towards the development of cancer therapies up to early clinical validation. Their aim is to eventually turn assets into de-risked clinical candidates.   Demonstrator Projects applicants may be eligible for up to 50% co-funding (maximum of €1.5 million per Demonstrator Project). The Oncode Accelerator program is a network of public and private partnerships from the Netherlands, including Leiden University, Leiden University Medical Center, the The Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht and the Oncode Accelerator Foundation. They receive funding from the Dutch National Growth Fund. Find out more on this FEBS Network post: https://lnkd.in/d8dXKipY

    Oncode Accelerator: The call for Demonstrator Projects is open!

    Oncode Accelerator: The call for Demonstrator Projects is open!

    network.febs.org

  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    🌟 Let's keep in touch! 🌟 Are you interested in staying up-to-date with developments of our program and how we progress towards our mission to outsmart cancer and impact lives? Join our mailing list to receive our Digital Magazine, updates about Demonstrator Projects, invitations to events and webinars and more interesting news and developments. 📩 Subscribe today via the link below👇 https://lnkd.in/g6Fk375S

    Subscribe to stay connected | Oncode Accelerator

    Subscribe to stay connected | Oncode Accelerator

    oncodeaccelerator.nl

  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    📢 The first call is open! 📢 In April, Oncode Accelerator announced the opening of the first call for the Demonstrator Projects. What is in it for you? Oncode Accelerator provides you with access to state-of-the-art equipment, world-class research institutes and industry, top scientists, and a dedicated team to manage the process of your Demonstrator Project from the start to the finish. Besides, a Demonstrator Project can receive co-funding from Oncode Accelerator. Oncode Accelerator invites all parties interested in our unique approach to apply for a Demonstrator Project focused on the preclinical development of cancer therapies. Read more about the Demonstrator Projects via the link below 👇

    What we offer | Oncode Accelerator

    What we offer | Oncode Accelerator

    oncodeaccelerator.nl

  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    🤖 AI in the detecting of prostate cancer 🤖 Research from one of our partners, Radboudumc, studied the use of an AI model in the detecting of prostate cancer. The study showed that the AI model detects prostate cancer more often and gives fewer false alarms than the radiologist. Using AI could thereby help to prevent unnecessary biopsies. In Sweden and Denmark, AI is also studied for the detection of breast cancer, which so far led to an increase in diagnoses when AI is used. However, AI is not yet used in the clinical setting and it might take a few more years for this to happen. Read the whole research article via this link: https://lnkd.in/enbxT4ya 

    • No alternative text description for this image
  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    🌟 Exciting Opportunity 🌟    Are you passionate about making a difference in cancer therapy development? We are expanding our team and seeking enthusiastic individuals to join us!    Oncode Accelerator foundation is currently looking for a Program Manager Demonstrators to facilitate the different program governance bodies. The Oncode Accelerator program is a cancer research network of 35 organizations that have joined forces innovate and accelerate the development of oncology treatments.    Check our vacancy here 👉 https://lnkd.in/eaPPRehg

    Program Manager Demonstrators

    Program Manager Demonstrators

    qtcrecruitment.com

  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    🌟 European Hematology Association (EHA) 2024 in Madrid 🌟 Workstream co-lead Cell and Gene Therapy, Jurgen Kuball, will present at the European Hematology Association (EHA) congress in Madrid. Jurgen will present on the GoCART initiative during the European Projects in Hematology session on Sunday June 16th between 8.30 and 9.30 AM. The mission of GoCART is to promote patient access to novel cellular therapies and to contribute to health and well-being through innovation by multi-stakeholder collaboration. Join the meeting and learn more!

    • No alternative text description for this image
  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    🌟 Looking back at a successful event 🌟 Recently, our public and private partners gathered for Oncode Accelerator's first Annual Event. Over 130 experts across different fields in oncology drug development came together to discuss how we can ‘Collaborate to Demonstrate’. We left the meeting with great excitement and have continued the discussions over the last days. We are keen to onboard new partners and demonstrators to join next steps in our journey in outsmarting cancer and improving lives. Read more about what Oncode Accelerator offers on our website: https://lnkd.in/efykuKfe

    • No alternative text description for this image
  • View organization page for Oncode Accelerator, graphic

    1,711 followers

    🌟 Great result with immunotherapy treatment 🌟 Researchers from one of our coordinating partners, Antoni van Leeuwenhoek, found that short treatment with immunotherapy was effective in 95% of patients with a certain type of colon cancer. Myriam Chalabi, internist-oncologist, is one of these researchers. Chalabi: ‘Now more than two years after treatment, the disease has not recurred in any patient, even though most of them were high-risk tumours. Read the whole news article via the link below 👇

    View organization page for Antoni van Leeuwenhoek, graphic

    39,526 followers

    Nog meer succes voor neo-adjuvante immuuntherapie: een kortdurende behandeling blijkt zeer effectief voor patiënten met een bepaalde vorm van darmkanker. De behandeling, die 4 weken in beslag nam, sloeg bij 95% van de patiënten zeer goed aan. Bij twee-derde van de patiënten bleek de tumor zelfs volledig verdwenen te zijn ten tijde van de operatie. Deze baanbrekende bevindingen komen voort uit de NICHE-2 studie van het Antoni van Leeuwenhoek en zijn gepubliceerd in de New England Journal of Medicine NEJM Group. Hier stopt het succes niet, want minstens zo belangrijk is het feit dat tot op heden bij geen van de patiënten de kanker teruggekeerd is in de ruim twee jaar dat ze gemiddeld zijn gevolgd. De eerste aanwijzingen voor het succes werden een paar jaar geleden al snel gevonden nadat internist-oncoloog Myriam Chalabi de NICHE-studie startte. Chalabi: “We wilden onderzoeken wat immuuntherapie kan betekenen voor mensen met niet uitgezaaide darmkanker. Wij hebben toen iets meegemaakt wat vrijwel nooit gebeurt, namelijk dat álle patiënten in een studiegroep goed reageren op een nieuwe behandeling.” Vier jaar geleden publiceerde Chalabi en haar collega’s de resultaten van dit onderzoek bij de eerste 20 patiënten met dit type darmkanker. “Deze 20 patiënten met een microsatelliet-instabiele darmkanker (MSI) hadden allemaal baat bij de behandeling, zoiets hadden we nooit eerder gezien.” Na dit succes werd de studie uitgebreid naar een grote groep patiënten om te onderzoeken of immuuntherapie ook op langere termijn uitzaaiingen kan voorkomen. De resultaten zijn dus opnieuw veelbelovend: de 111 patiënten met MSI-darmkanker die zijn behandeld reageren nagenoeg allemaal zeer goed op deze zeer korte voorbehandeling met immuuntherapie. Chalabi: “Nu ruim twee jaar na de behandeling is de ziekte bij geen enkele patiënt teruggekomen, terwijl het grotendeels tumoren met een hoog risico waren. De resultaten zijn ongekend. Zowel het effect als ook de bijwerkingen zijn veel beter dan bijvoorbeeld chemotherapie voorafgaand aan de operatie, waarop maar 1 op de 20 patiënten reageert.” Lees hier het nieuwsbericht ➡️ https://bit.ly/4e2B7Om #hetAVL #NKI #immuuntherapie #neoadjuvant #kankeronderzoek #darmkanker

    Immuuntherapie voor operatie zeer succesvol bij darmkanker | AVL

    Immuuntherapie voor operatie zeer succesvol bij darmkanker | AVL

    avl.nl

Similar pages